Feb 14, 2012, 09.01 PM IST

Parenteral Drug Dec '11 sales at Rs 64.60 crore

Parenteral Drugs (India) has reported a sales turnover of Rs 64.60 crore and a net loss of Rs 0.59 crore for the quarter ended Dec '11

Source: Moneycontrol.com
Share Share on Tumblr
Share  .  Email  .  Print  .  A+
Parenteral Drugs (India) has reported a sales turnover of Rs 64.60 crore and a net loss of Rs 0.59 crore for the quarter ended Dec '11.
For the quarter ended Dec 2010 the sales turnover was Rs 127.70 crore and net profit was Rs 15.00 crore.
Quarterly Results of Parenteral Drugs (India)-------- in Rs. Cr. --------
Dec '10Sep '11Dec '11
Sales Turnover127.7061.0864.60
Other Income------
Total Income127.7061.0864.60
Total Expenses101.1955.4551.82
Operating Profit26.515.6312.78
Profit On Sale Of Assets------
Profit On Sale Of Investments------
Gain/Loss On Foreign Exchange------
VRS Adjustment------
Other Extraordinary Income/Expenses------
Total Extraordinary Income/Expenses------
Tax On Extraordinary Items------
Net Extra Ordinary Income/Expenses------
Gross Profit26.515.6312.78
Interest5.609.319.85
PBDT20.92-3.682.94
Depreciation1.972.603.01
Depreciation On Revaluation Of Assets------
PBT18.95-6.28-0.07
Tax3.950.520.52
Net Profit15.00-6.80-0.59
Prior Years Income/Expenses------
Depreciation for Previous Years Written Back/ Provided------
Dividend------
Dividend Tax------
Dividend (%)------
Earnings Per Share5.80----
Book Value------
Equity25.8725.8725.87
Reserves------
Face Value10.0010.0010.00
Source : Dion Global Solutions Limited

Set email alert for

Action in Parenteral Drugs (India)
Humble Bundle with Android 6 now available
After jail, Sreesanth to get married to girl from Jaipur "After jail, Sreesanth to get married to girl from Jaipur"

From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'

The latest earning numbers FIRST on CNBC-TV18
News Videos

Jun 19 2013, 12:44

Rupee paying for govt mess; don`t like gold NBFCs: HDFC Sec

- in MARKET OUTLOOK

Jun 19 2013, 12:44

Weak rupee to benefit export oriented IT cos: Dipan Mehta

- in MARKET OUTLOOK